Istanbul University's Institute of Oncology, established in 1982, combines medical, radiation and paediatric oncology with cancer epidemiology; its breast programme is one of Turkey's largest, its paediatric unit is a national referral centre, and it trains a large share of Turkish oncologists.
Established in 1982 within Istanbul University, the Institute of Oncology combines clinical departments of medical, radiation and paediatric oncology with basic oncology, cancer epidemiology and prevention. Its breast cancer programme under investigators such as Adnan Aydıner and Pınar Saip is one of the largest in Turkey, Rejin Kebudi's paediatric oncology unit is a national referral centre, and the institute trains a large share of Turkish oncologists. It participates in Turkish Oncology Group and international trials, runs molecular pathology and genetic counselling services, and works with the Istanbul Faculty of Medicine's surgical and nuclear medicine departments.
Shares Brachytherapy, Most of the world has almost no cancer care, Comprehensive genomic profiling, Head and neck squamous cell carcinoma.
Shares Brachytherapy, Most of the world has almost no cancer care, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).
Shares Brachytherapy, Most of the world has almost no cancer care, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam).
Shares Brachytherapy, Head and neck squamous cell carcinoma, HR-positive / HER2-negative breast cancer, Non-small-cell lung cancer.
Shares Brachytherapy, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
Shares Brachytherapy, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
Shares Brachytherapy, Head and neck squamous cell carcinoma, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.
Shares Brachytherapy, Comprehensive genomic profiling, IMRT / IGRT (modern external beam), HR-positive / HER2-negative breast cancer.